Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Antithrombin therapy is a standard treatment for acute coronary syndromes (ACS).
• Recent trials show mixed results for enoxaparin and unfractionated heparin efficacy and safety in ACS.
• A systematic evaluation is needed to clarify comparative outcomes.

Purpose of the Study:

• To systematically evaluate death, myocardial infarction (MI), transfusion, and bleeding in randomized controlled trials comparing enoxaparin and unfractionated heparin for ACS.
• To analyze outcomes in the overall ACS population and in patients not receiving prior antithrombin therapy.

Main Methods:

• Systematic review and meta-analysis of 6 randomized controlled trials involving 21,946 ACS patients.
• Data extracted from primary datasets and principal investigators.
• Random-effects empirical Bayes model used for outcome evaluation.

Main Results:

• No significant difference in 30-day all-cause death between enoxaparin and unfractionated heparin.
• Enoxaparin significantly reduced the combined endpoint of death or nonfatal MI at 30 days (OR, 0.91; 95% CI, 0.83-0.99).
• This benefit was more pronounced in patients without prior antithrombin therapy (OR, 0.81; 95% CI, 0.70-0.94).
• No significant differences in transfusion or major bleeding rates were observed.

Conclusions:

• Enoxaparin is more effective than unfractionated heparin in reducing the combined endpoint of death or MI in ACS patients.
• The findings support enoxaparin's role in ACS management, particularly in specific patient subgroups.
• Further research may refine antithrombin selection based on patient characteristics and prior treatments.